UK regulatory context
Advertising rules for weight-loss medicines
Educational explainer on UK rules restricting public advertising of prescription-only weight-loss and incretin medicines. Covers MHRA, ASA / CAP context, and the difference between education and promotion.
Two regulators, one principle
UK rules on the promotion of medicines are shaped by two overlapping frameworks. The MHRA oversees medicines advertising under the Human Medicines Regulations 2012. The Advertising Standards Authority (ASA), under the Committee of Advertising Practice (CAP) Code, oversees advertising more generally and applies specific restrictions to medicine claims. Both regimes point in the same direction for prescription-only medicines (POMs): public-facing promotion is restricted.
What is restricted for POMs
- Direct-to-public advertising encouraging the purchase or use of a specific POM.
- Promotional claims about efficacy or safety beyond the product information.
- Before-and-after imagery in weight-loss medicine marketing.
- Influencer and testimonial-led promotion of POMs to the public.
- Claims of guaranteed outcomes, miraculous effects, or risk-free use.
What is permitted
- Educational and journalistic content explaining how the medicine works, what trials report and what the safety profile is.
- Healthcare-professional information consistent with the licensed product information.
- Patient information leaflets and SmPC content for the licensed product.
Where many online operators get this wrong
- Disguising direct-response medicine advertising as "information" pages.
- Affiliate funnels where editorial language is the disguise for a sales channel.
- Before / after imagery or transformation marketing for POM injectables.
- Influencer testimonials and endorsements of named POMs.
- Cross-border marketing that ignores UK-specific advertising restrictions for POMs.
How this site applies the rules
- No supplier directory, no online-pharmacy ranking, no compounder ranking.
- No before / after imagery, no testimonials of weight loss, no influencer-style claims.
- No promotional language about "best", "cheap", "fastest", "guaranteed" or "miracle".
- No external links optimised for conversion to a medicine-supply funnel.
- Editorial language only, with evidence-led framing and full last-reviewed dates.
- It is not a substitute for legal advice on a specific advertising claim. Consult the ASA, CAP or a qualified solicitor for that.
- It is not a list of permitted promotional tactics.
- It is not an endorsement of any specific clinic or telehealth provider.
Related UK regulatory topics
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK authority for medicines advertising standards and enforcement
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency
EMA guidance on promotion of medicinal products
- Regulatory document (MHRA/EMA/FDA)FDA — U.S. Food and Drug Administration
FDA direct-to-consumer advertising rules for comparator reference
- Regulatory document (MHRA/EMA/FDA)ASA — Advertising Standards Authority
UK advertising self-regulatory body; BCAP Code governs weight-loss claims